HC Wainwright Increases NovoCure Price Target to $49.00

The medical equipment provider's stock received a "buy" rating and a price target increase.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

HC Wainwright, an investment banking firm, has increased its price target for shares of NovoCure (NASDAQ:NVCR) from $47.00 to $49.00 and maintained a "buy" rating on the stock. NovoCure is a medical equipment provider that specializes in Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors.

Why it matters

The price target increase and buy rating from HC Wainwright suggest the firm believes NovoCure's stock has significant upside potential, which could be positive news for investors. NovoCure's TTFields technology is a unique approach to cancer treatment that may provide an alternative modality to complement existing therapies.

The details

In its report, HC Wainwright cited NovoCure's potential for growth and the promise of its TTFields technology as reasons for the price target increase. The firm believes NovoCure's stock could rise as much as 263.50% from its current trading price.

  • HC Wainwright issued the updated price target and rating on Thursday, February 26, 2026.

The players

NovoCure

A global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors.

HC Wainwright

An investment banking firm that provides research coverage and investment banking services.

Got photos? Submit your photos here. ›

The takeaway

The price target increase and buy rating from HC Wainwright suggest the firm sees significant upside potential in NovoCure's stock, driven by the company's innovative TTFields technology and its potential to provide an alternative cancer treatment option.